+

WO1993013786A1 - Formulation and use of microorganisms in treating livestock - Google Patents

Formulation and use of microorganisms in treating livestock Download PDF

Info

Publication number
WO1993013786A1
WO1993013786A1 PCT/GB1993/000065 GB9300065W WO9313786A1 WO 1993013786 A1 WO1993013786 A1 WO 1993013786A1 GB 9300065 W GB9300065 W GB 9300065W WO 9313786 A1 WO9313786 A1 WO 9313786A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation according
formulation
microorganisms
microorganism
animal
Prior art date
Application number
PCT/GB1993/000065
Other languages
French (fr)
Inventor
Stephen Philip Mann
Original Assignee
Stephen Philip Mann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stephen Philip Mann filed Critical Stephen Philip Mann
Priority to DE69322766T priority Critical patent/DE69322766D1/en
Priority to US08/256,657 priority patent/US5718894A/en
Priority to AU32640/93A priority patent/AU667070B2/en
Priority to JP5512272A priority patent/JPH07503004A/en
Priority to EP93901859A priority patent/EP0623022B1/en
Publication of WO1993013786A1 publication Critical patent/WO1993013786A1/en
Priority to NO942675A priority patent/NO942675D0/en
Priority to FI943387A priority patent/FI943387L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/189—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase

Definitions

  • This invention relates to a formulation of microorganisms suitable for administration to an animal, for therapeutic purposes or to promote growth, weight gain or another desirable aim in commercial livestock.
  • GIT gastrointestinal tract
  • stress a period of vulnerability to infection of the gastrointestinal tract
  • the first manifestation of deleterious effects occurring is usually a loosening of bowel function and diarrhoea.
  • the effect of sub-acute infections is a marked check in the animals' growth, that can even lead to a loss in weight.
  • the periods of "stress” occur, they prove less traumatic, as seen by the reduced occurrence of the symptoms described above.
  • the effects of "stress” may be both intensified and prolonged, and additional traumas such as maternal separation, transport, human handling and unusual environments may be introduced.
  • antibiotics such as tylosin are added to the animal feed to prevent or reduce GIT infections. Growth of the animals is thus promoted, when compared with untreated controls, by preventing the onset of the debilitating effects of the GIT infections.
  • the addition of copper to the feed is also common practice, but the mechanism of action is uncertain. It has however been shown that the presence of copper, under certain conditions, can lead to the production of H 2 0 2 , which is also produced by the action of bacteria in the GIT.
  • a novel formulation of microorganisms is both capable of producing lactic acid in the GIT and also of producing (directly or indirectly. in situ) , a bactericide to which the microorganisms in the formulation are resistant.
  • the microorganisms in the novel formulation severally and collectively produce compounds and enzymes that encourage the establishment of a predominant and benign flora in the GIT of mammalian, avian and piscine species. The establishment of such a flora prevents the onset of those gastrointestinal diseases caused by the establishment of an alternative and deleterious flora in the intestine.
  • the mode of action of these bacteria is to produce antimicrobial enzymes, bactericides and bacteriostats which prevent the establishment of bacteria other than those administered.
  • This by contrast to the disadvantages associated with current techniques for achieving the same aims, i.e. by using a combination of aseptic husbandry with the addition of antibiotics and high concentrations of copper to animal feeds.
  • the principles described herein are applicable to a wide variety of animal species and commercial practices.
  • the establishment of appropriate benign flora may be considered in the GIT of many animals that are used for the commercial production of meat, milk and fish.
  • an object of the invention is to improve the health and well-being of animals in general, its use and applicability can be extended to draught animals, companion animals and humans.
  • a first microorganism in the novel formulation has the capability of producing lactic acid in the GIT.
  • This microorganism is, for example, of the genus Lactobacillus or Enterococcus. Either or both genera may be used; they are distinguished by their ability to utilise sugars such as glucose or lactose or, in the case of Enterococcus. to utilise starch, to produce lactic acid and thus reduce the local pH.
  • the choice of microorganism will depend on the locus at which it is desired to give the desired effect; for example, microorganisms of the genus Lactobacillus produce lactic acid at a more acid pH than those of the genus Enterococcus. Species of each of these genera that may be used are L. kasei. L. aminosum, L. fermentum. IS. faecalis and E. faecium. A mixture of more than one of each such microorganism may be used.
  • a second microorganism that is used is capable of producing a bactericide, e.g. by providing a substrate for lactoperoxidase, to produce peroxide.
  • the other microorganisms in the formulation should be resistant to that bactericide.
  • Such a bactericide is capable of combating microorganisms that are the positive agent of enteric disorders, e.g. Staphylococcus aureus. E. coli and Salmonella.
  • the use of microorganisms ensures that the desired effect is produced locally.
  • the various microorganisms in the formulation should be compatible, e.g. capable of growing together. Fast growth at the locus of action is desirable.
  • the microorganisms may be selected for various characteristics, e.g. resistance to commercial antibiotics and also bile acids, that make them suitable for their intended use.
  • the formulation may be supplemented with enzymes, or microorganisms producing enzymes, which digest fibre.
  • enzymes include arabinase and xylanase.
  • Another useful enzyme is glucose oxidase, to produce (additional) peroxide.
  • enzymes or biocatalysts producing free radicals from peroxide e.g. lactoperoxidase
  • lactoperoxidase may be added to supplement or replace the natural enzymes found in milk.
  • free radicals have a disinfectant effect on some organisms that are generally not effective on the selected strains in vivo.
  • a formulation of the invention can be used initially with the administration of conventional antibiotics.
  • microorganisms that are used in the novel formulation are selected for their ability to produce compounds such as bacteriocins and other such compounds in sufficient quantities to prevent the establishment of the deleterious bacteria in the GIT (e.g.
  • E. coli. Salmonella etc. The bacteria can be isolated from wild or cross-bred animals kept under non-intensive husbandry conditions. The quantities of the antimicrobial produced by these bacteria, however, remains small compared with the concentrations of antibiotics currently added to animal feeds. The possibility of the emergence of resistant strains is therefore much reduced. Further, by using a number of such compounds, the possibility of undesirable bacteria establishing resistance to a single agent is reduced.
  • Anti-bacterial compounds in this context will cover a wide range of compounds and are not con ined to those generally referred to as antibiotics, though the production of antibiotics in vivo is part of the synergic effects that may be observed.
  • the anti-bacterial compounds include those that produce bacteriocins, lactic acid, peroxide and enzymes.
  • enzymes may be added to the formulation prior to ingestion, to enhance the establishment of the bacteria. Thus the inclusion of amylase and/or peroxidase will assist in the establishment of the desired flora.
  • the establishment of the desirable and benign flora depends on the selection of complementary species and strains that will establish themselves in most if not all of the ecological niches that are to be found in the GIT. Such ecological areas could under other conditions harbour undesirable organisms.
  • the selected microorganisms must, however, be sufficiently compatible to be specific to a particular environment, or resistant to the metabolic products of the other organisms to be used.
  • the desired flora must be established in competition with an already established flora. In the GIT of young animals, it is necessary to saturate as far as is possible the environment of the young animal with the desired flora. To this end, the formulation is fed to animals prior to parturition, following an intense course of administration of the formulation after administration of a course of antibiotics, or together with a compatible antibiotic.
  • the administration of the formulation to the young animals, post-parturition is preferably immediate and supplemented with a continuous administration with the feed.
  • strains of the organisms are preferably selected or produced that are resistant to the temperatures, e.g. 45°C or more, encountered during the manufacturing and pelleting processes.
  • the invention will now be described in terms of a formulation suitable for use in pigs.
  • the intention is to remove synthetic antibiotics and copper from feed. It derives from observations that the flora in the GIT of wild-type pigs, kept under non- intensive conditions of husbandry, varies with age, and that a number of species tend to dominate during the stages of development. Three genera are found consistently: Lactobacilli. Enterococci and Bacilli. Of these, the E. faecalis and E. faecium predominate during the early stages of the animals' life. Lactobacilli are present from the earliest stages of life through to adulthood. Bacilli are present throughout, but become particularly numerous with the onset of an adult diet. This flora is notable for a number of reasons:
  • the bacteria all grow at low values of pH and all produce acid (usually but not exclusively lactic acid) .
  • the Bacilli in particular produce anti-bacterial compounds (e.g. bacitracin and polymyxin) while the Enterococci appear to be resistant to the release of such compounds (particularly bacitracin) .
  • All these bacteria can use lactose as a carbon source and therefore have the ability to predominate in the presence of a milk diet containing lactose.
  • the organisms as a whole can use a wide variety of carbon sources including structural (plant) polysaccharides which enables them to colonise the GIT over all stages of the animals' life.
  • Lactobacilli and the Streptococci all produce peroxide which in combination with the lactoperoxidase in milk and saliva produces a natural bactericide. This should permit the removal of copper from the diet since one putative mechanism for the copper in the diet is the production of peroxide in the presence of ascorbic acid.
  • a formulation for use in pigs (but also other animals, e.g. man) is composed of four strains selected to show heat tolerance. Each strain is used at 10 cfu/g.
  • All strains are capable of anaerobic growth and of utilising lactose and, except for the E. faecium. sucrose.
  • Two strains of Bacillus are used, each capable of utilising arabinose, starch, pectin and araban, of growth on beet pulp, of inhibiting £. aureus, Salmonella and E. coli, and of producing xylanase and arabinofuranase, and each resistant to the antibiotics bacitracin, virginiamycin and tylosin (to a degree) , and to porcine bile extract. They each grow in the relatively high pH of the hind gut.
  • the other strains are producers of lactate and all are resistant to porcine bile extract and the antibiotics given above, except that Lactobacillus and E. faecalis strains may not be resistant to bacitracin. This apparent disadvantage is countered by the practical aspect that these strains grow at low pH and are not affected by bacitracin in the upper intestine, where the production of lactate is important.
  • the formulation may be supplemented by the addition of one or more enzymes selected from peroxidase, lipase, glucose oxidase, amylase and glucanase.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

For therapeutic use, and particularly for promoting growth or weight gain in livestock under intensive husbandry, a formulation comprises a first microorganism capable of producing lactic acid in the gastrointestinal tract of the animal and a second microorganism capable of producing a bactericide to which the microorganisms are resistant. The formulation may also comprise the means for digesting fibre and/or lactoperoxidase.

Description

FORMULATION AND USE OF MICROORGANISMS IN TREATING LIVESTOCK Field of the Invention
This invention relates to a formulation of microorganisms suitable for administration to an animal, for therapeutic purposes or to promote growth, weight gain or another desirable aim in commercial livestock. Background of the Invention
In the production and growth of all animals, it is possible to identify periods of vulnerability to infection of the gastrointestinal tract (GIT) , e.g. parturition and weaning, and other periods of a traumatic nature that are generally referred to as "stress". During these periods of change, the first manifestation of deleterious effects occurring is usually a loosening of bowel function and diarrhoea. In extreme cases, such symptoms can lead to the onset of dehydration, and ultimately death. The effect of sub-acute infections is a marked check in the animals' growth, that can even lead to a loss in weight. In the wild, although the periods of "stress" occur, they prove less traumatic, as seen by the reduced occurrence of the symptoms described above. By contrast, under conditions of normal and intensive husbandry, the effects of "stress" may be both intensified and prolonged, and additional traumas such as maternal separation, transport, human handling and unusual environments may be introduced.
In current practice of intensive husbandry in pigs, antibiotics such as tylosin are added to the animal feed to prevent or reduce GIT infections. Growth of the animals is thus promoted, when compared with untreated controls, by preventing the onset of the debilitating effects of the GIT infections. The addition of copper to the feed is also common practice, but the mechanism of action is uncertain. It has however been shown that the presence of copper, under certain conditions, can lead to the production of H202, which is also produced by the action of bacteria in the GIT.
Summary of the Invention
A novel formulation of microorganisms, according to the present invention, is both capable of producing lactic acid in the GIT and also of producing (directly or indirectly. in situ) , a bactericide to which the microorganisms in the formulation are resistant. Description of the Invention The microorganisms in the novel formulation severally and collectively produce compounds and enzymes that encourage the establishment of a predominant and benign flora in the GIT of mammalian, avian and piscine species. The establishment of such a flora prevents the onset of those gastrointestinal diseases caused by the establishment of an alternative and deleterious flora in the intestine. The mode of action of these bacteria is to produce antimicrobial enzymes, bactericides and bacteriostats which prevent the establishment of bacteria other than those administered. This by contrast to the disadvantages associated with current techniques for achieving the same aims, i.e. by using a combination of aseptic husbandry with the addition of antibiotics and high concentrations of copper to animal feeds. The principles described herein are applicable to a wide variety of animal species and commercial practices. The establishment of appropriate benign flora may be considered in the GIT of many animals that are used for the commercial production of meat, milk and fish. In addition, since an object of the invention is to improve the health and well-being of animals in general, its use and applicability can be extended to draught animals, companion animals and humans.
A first microorganism in the novel formulation has the capability of producing lactic acid in the GIT. This microorganism is, for example, of the genus Lactobacillus or Enterococcus. Either or both genera may be used; they are distinguished by their ability to utilise sugars such as glucose or lactose or, in the case of Enterococcus. to utilise starch, to produce lactic acid and thus reduce the local pH. The choice of microorganism will depend on the locus at which it is desired to give the desired effect; for example, microorganisms of the genus Lactobacillus produce lactic acid at a more acid pH than those of the genus Enterococcus. Species of each of these genera that may be used are L. kasei. L. aminosum, L. fermentum. IS. faecalis and E. faecium. A mixture of more than one of each such microorganism may be used.
A second microorganism that is used is capable of producing a bactericide, e.g. by providing a substrate for lactoperoxidase, to produce peroxide. The other microorganisms in the formulation should be resistant to that bactericide. Such a bactericide is capable of combating microorganisms that are the positive agent of enteric disorders, e.g. Staphylococcus aureus. E. coli and Salmonella. The use of microorganisms ensures that the desired effect is produced locally. The various microorganisms in the formulation should be compatible, e.g. capable of growing together. Fast growth at the locus of action is desirable. The microorganisms may be selected for various characteristics, e.g. resistance to commercial antibiotics and also bile acids, that make them suitable for their intended use.
The formulation may be supplemented with enzymes, or microorganisms producing enzymes, which digest fibre. Such enzymes include arabinase and xylanase. Another useful enzyme is glucose oxidase, to produce (additional) peroxide. In addition, enzymes or biocatalysts producing free radicals from peroxide, e.g. lactoperoxidase, may be added to supplement or replace the natural enzymes found in milk. Such free radicals have a disinfectant effect on some organisms that are generally not effective on the selected strains in vivo. A formulation of the invention can be used initially with the administration of conventional antibiotics.
However, its continuing administration allows the amount of tylosin, virginiamycin or similar antibiotic to be reduced, and the requirement for copper in animal feeds can also thus be reduced or prevented. The microorganisms that are used in the novel formulation are selected for their ability to produce compounds such as bacteriocins and other such compounds in sufficient quantities to prevent the establishment of the deleterious bacteria in the GIT (e.g.
E. coli. Salmonella etc.). The bacteria can be isolated from wild or cross-bred animals kept under non-intensive husbandry conditions. The quantities of the antimicrobial produced by these bacteria, however, remains small compared with the concentrations of antibiotics currently added to animal feeds. The possibility of the emergence of resistant strains is therefore much reduced. Further, by using a number of such compounds, the possibility of undesirable bacteria establishing resistance to a single agent is reduced.
Anti-bacterial compounds in this context will cover a wide range of compounds and are not con ined to those generally referred to as antibiotics, though the production of antibiotics in vivo is part of the synergic effects that may be observed. The anti-bacterial compounds include those that produce bacteriocins, lactic acid, peroxide and enzymes. In addition, enzymes may be added to the formulation prior to ingestion, to enhance the establishment of the bacteria. Thus the inclusion of amylase and/or peroxidase will assist in the establishment of the desired flora.
The establishment of the desirable and benign flora depends on the selection of complementary species and strains that will establish themselves in most if not all of the ecological niches that are to be found in the GIT. Such ecological areas could under other conditions harbour undesirable organisms. The selected microorganisms must, however, be sufficiently compatible to be specific to a particular environment, or resistant to the metabolic products of the other organisms to be used.
The desired flora must be established in competition with an already established flora. In the GIT of young animals, it is necessary to saturate as far as is possible the environment of the young animal with the desired flora. To this end, the formulation is fed to animals prior to parturition, following an intense course of administration of the formulation after administration of a course of antibiotics, or together with a compatible antibiotic. The administration of the formulation to the young animals, post-parturition, is preferably immediate and supplemented with a continuous administration with the feed. For this purpose, and in consideration of the processes of preparation of commercial animal feeds, strains of the organisms are preferably selected or produced that are resistant to the temperatures, e.g. 45°C or more, encountered during the manufacturing and pelleting processes.
By way of illustration only, the invention will now be described in terms of a formulation suitable for use in pigs. The intention is to remove synthetic antibiotics and copper from feed. It derives from observations that the flora in the GIT of wild-type pigs, kept under non- intensive conditions of husbandry, varies with age, and that a number of species tend to dominate during the stages of development. Three genera are found consistently: Lactobacilli. Enterococci and Bacilli. Of these, the E. faecalis and E. faecium predominate during the early stages of the animals' life. Lactobacilli are present from the earliest stages of life through to adulthood. Bacilli are present throughout, but become particularly numerous with the onset of an adult diet. This flora is notable for a number of reasons:
1. The bacteria all grow at low values of pH and all produce acid (usually but not exclusively lactic acid) . 2. The Bacilli in particular produce anti-bacterial compounds (e.g. bacitracin and polymyxin) while the Enterococci appear to be resistant to the release of such compounds (particularly bacitracin) . 3. All these bacteria can use lactose as a carbon source and therefore have the ability to predominate in the presence of a milk diet containing lactose.
4. In addition, the organisms as a whole can use a wide variety of carbon sources including structural (plant) polysaccharides which enables them to colonise the GIT over all stages of the animals' life.
5. The Lactobacilli and the Streptococci all produce peroxide which in combination with the lactoperoxidase in milk and saliva produces a natural bactericide. This should permit the removal of copper from the diet since one putative mechanism for the copper in the diet is the production of peroxide in the presence of ascorbic acid. Example
A formulation for use in pigs (but also other animals, e.g. man) is composed of four strains selected to show heat tolerance. Each strain is used at 10 cfu/g.
Figure imgf000008_0001
All strains are capable of anaerobic growth and of utilising lactose and, except for the E. faecium. sucrose. Two strains of Bacillus are used, each capable of utilising arabinose, starch, pectin and araban, of growth on beet pulp, of inhibiting £. aureus, Salmonella and E. coli, and of producing xylanase and arabinofuranase, and each resistant to the antibiotics bacitracin, virginiamycin and tylosin (to a degree) , and to porcine bile extract. They each grow in the relatively high pH of the hind gut.
The other strains (Lactobacillus and Enterococcus) are producers of lactate and all are resistant to porcine bile extract and the antibiotics given above, except that Lactobacillus and E. faecalis strains may not be resistant to bacitracin. This apparent disadvantage is countered by the practical aspect that these strains grow at low pH and are not affected by bacitracin in the upper intestine, where the production of lactate is important.
The formulation may be supplemented by the addition of one or more enzymes selected from peroxidase, lipase, glucose oxidase, amylase and glucanase.
In initial trials, this formulation has been shown to allow the replacement of antibiotic feed additives and copper in pigs, while mimicking the beneficial effects of such additives. A reduction in the presence of harmful microorganisms, as evidenced by the absence of the MMA syndrome, was observed.

Claims

1. A formulation of microorganisms suitable for administration to an animal, comprising a first microorganism capable of producing lactic acid in the gastrointestinal tract of the animal and a second microorganism capable of producing a bactericide to which the microorganisms are resistant.
2. A formulation according to claim 1, wherein the first microorganism is a Lactobacillus.
3. A formulation according to claim 1 or claim 2, wherein the first microorganism is an Enterococcus.
4. A formulation according to any preceding claim, wherein the second microorganism is a Bacillus.
5. A formulation according to any preceding claim, which comprises a fibre-digesting enzyme or a microorganism capable of producing a fibre-digesting enzyme.
6. A formulation according to any preceding claim, which additionally comprises lactoperoxidase.
7. A formulation according to any preceding claim, wherein each component thereof is resistant to the antibacterial products of the or each other component.
8. A formulation according to any preceding claim, wherein the or each component thereof is resistant to synthetic antibiotics used to combat pathogens of the gastrointestinal tract such as E. coli.
9. A formulation according to any preceding claim, characterised by the ability to reduce the growth rates of harmful enteric bacteria such as E. coli. Salmonella and Clostridia.
10. Use of the components defined in a formulation according to any preceding claim for the promotion of growth or weight gain in a farm animal.
11. A composition comprising the components of a formulation according to any preceding claim, for simultaneous, separate of sequential use in the treatment of an animal or human.
PCT/GB1993/000065 1992-01-16 1993-01-13 Formulation and use of microorganisms in treating livestock WO1993013786A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE69322766T DE69322766D1 (en) 1992-01-16 1993-01-13 FORMULATION AND USE OF MICROORGANISMS FOR THE TREATMENT OF LIVESTOCK
US08/256,657 US5718894A (en) 1992-01-16 1993-01-13 Formulation and use of microorganisms in treating livestock
AU32640/93A AU667070B2 (en) 1992-01-16 1993-01-13 Formulation and use of microorganisms in treating livestock
JP5512272A JPH07503004A (en) 1992-01-16 1993-01-13 Preparations and uses of microorganisms in treating livestock
EP93901859A EP0623022B1 (en) 1992-01-16 1993-01-13 Formulation and use of microorganisms in treating livestock
NO942675A NO942675D0 (en) 1992-01-16 1994-07-15 Formulation and use of microorganisms in the treatment of cattle
FI943387A FI943387L (en) 1992-01-16 1994-07-15 Microorganism formula and the use of microorganisms in livestock management

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9200891.1 1992-01-16
GB929200891A GB9200891D0 (en) 1992-01-16 1992-01-16 Formulation of microorganisms

Publications (1)

Publication Number Publication Date
WO1993013786A1 true WO1993013786A1 (en) 1993-07-22

Family

ID=10708691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/000065 WO1993013786A1 (en) 1992-01-16 1993-01-13 Formulation and use of microorganisms in treating livestock

Country Status (12)

Country Link
US (1) US5718894A (en)
EP (1) EP0623022B1 (en)
JP (1) JPH07503004A (en)
AT (1) ATE174797T1 (en)
AU (1) AU667070B2 (en)
CA (1) CA2128002A1 (en)
DE (1) DE69322766D1 (en)
FI (1) FI943387L (en)
GB (1) GB9200891D0 (en)
NO (1) NO942675D0 (en)
NZ (1) NZ246376A (en)
WO (1) WO1993013786A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015682A1 (en) * 1994-11-22 1996-05-30 Ing. Erich Erber Kommanditgesellschaft Fodder and drinking water additive for improving the resistance to stress and immunity of useful animals
EP0681787A3 (en) * 1994-05-10 1996-10-23 Finnfeeds Int Ltd Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis.
FR2733119A1 (en) * 1995-04-05 1996-10-25 Tsa Fa Hung PROCESS FOR BREEDING CHICKENS
EP0852114A1 (en) * 1997-01-06 1998-07-08 Cobiotex Processes for the systematic eradication of pathogenic agents carried by animals and compositions used in these processes
WO1999003497A1 (en) * 1997-07-18 1999-01-28 Finnfeeds International Ltd. Use of an enzyme for the manufacture of an agent for controlling bacterial infection
WO2000021381A1 (en) * 1998-10-15 2000-04-20 Dsm N.V. Antimicrobial enzymes in animal feed
US7799551B2 (en) 2004-09-01 2010-09-21 Pioneer Hi-Bred International, Inc. Ferulate esterase producing strains and methods of using same
US7919683B2 (en) 2006-11-13 2011-04-05 Pioneer Hi-Bred International, Inc. Cloning and sequencing of the ferulate esterase gene from Lactobacillus buchneri LN4017
WO2012096500A3 (en) * 2011-01-11 2012-11-22 광주시농업기술센터 Probiotic composition for livestock, and method for preparing same
US9822334B2 (en) 2014-03-07 2017-11-21 Pioneer Hi-Bred International, Inc. Rapid acting lactobacillus strains and their use to improve aerobic stability of silage
WO2019095935A1 (en) * 2017-11-20 2019-05-23 济南百斯杰生物工程有限公司 Microecological formulation compatible with glucose oxidase, preparation method therefor and use thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876621A (en) * 1997-09-30 1999-03-02 Sapienza; Richard Environmentally benign anti-icing or deicing fluids
RU2151607C1 (en) * 1999-09-20 2000-06-27 Оренбургская государственная медицинская академия Method for correcting hyperglykemia in the cases of pancreonecrosis
GB0208999D0 (en) * 2002-04-19 2002-05-29 Isp Alginates Uk Ltd Process, equipment and products
WO2005000034A2 (en) * 2003-06-23 2005-01-06 Agtech Products, Inc. Lactic bacteria and its use in direct-fed microbials
EP1510135A1 (en) * 2003-08-26 2005-03-02 Chr. Hansen A/S A farm animal feed product with probiotic enterococcus bacteria
CA2566617C (en) 2004-05-14 2013-12-31 Agtech Products, Inc. Method and composition for reducing e.coli disease and enhancing performance using bacillus
US20060039899A1 (en) * 2004-08-23 2006-02-23 Winn Robert T Animal nutritional product that increases weight gain and reduces diarrhea morbidity, mortality and severity by stimulation of natural immune response, nutritional support of immune function and supplemental nutricines and probiotics
US7241437B2 (en) * 2004-12-30 2007-07-10 3M Innovative Properties Company Zirconia particles
US7754469B2 (en) * 2005-11-30 2010-07-13 Agtech Products, Inc Microorganisms and methods for treating poultry
FR2921257B1 (en) * 2007-09-21 2009-11-06 Exsymol Sa TOPICAL USE OF THIAZOLIDINE DERIVATIVES FROM THE CONSEQUENCES OF OXIDATIVE SKIN STRESS
US8021654B2 (en) * 2008-03-14 2011-09-20 Danisco A/S Methods of treating pigs with Bacillus strains
CA2721180C (en) 2008-04-17 2016-10-11 Danisco A/S Bacillus strains useful for animal odor control
US8540981B1 (en) 2008-07-07 2013-09-24 Dupont Nutrition Biosciences Aps Bacillus strains useful against calf pathogens and scours
US8557234B1 (en) 2011-05-18 2013-10-15 Dupont Nutrition Biosciences Aps Methods of controlling pit foam
CN103930540B (en) 2011-08-24 2017-05-17 杜邦营养生物科学有限公司 Enzyme producing bacillus strains
US20130247831A1 (en) * 2012-03-26 2013-09-26 Kyle Clark Howes Method of treating an animal
FR3026110B1 (en) 2014-09-24 2016-11-18 Commissariat Energie Atomique PROCESS FOR RECOVERING THE PLATINUM PRESENT IN A MEMBRANE-ELECTRODE ASSEMBLY
DK3417057T3 (en) * 2016-02-18 2022-07-04 Biopract Gmbh Arabinanase and uses thereof
CN108012986A (en) * 2017-11-30 2018-05-11 云南牧道生物技术有限公司 It is a kind of reduce copper accumulated in growing and fattening pigs body and pig manure in content method

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1040278A (en) * 1963-10-15 1966-08-24 Analyses Et De Rech S Biolog M Bacterial compositions for the regeneration of the intestinal microflora
EP0208818A1 (en) * 1984-01-17 1987-01-21 Seikenkai Foundational Juridical Person Biodeodorizer and the process for the preparation thereof
EP0290410A2 (en) * 1987-05-05 1988-11-09 Ewos Aktiebolag Food and feedstuff
US4808417A (en) * 1986-12-27 1989-02-28 Toa Pharmaceutical Co., Ltd. Feed additive for fish cultivation
WO1989011858A1 (en) * 1988-06-09 1989-12-14 Whitecliffe Laboratories Limited Treatment of immunodeficiency
EP0397227A1 (en) * 1989-05-12 1990-11-14 Bio Serae Laboratoires Sa Method of preparation of an antimicrobial particulate, its product and applications

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875306A (en) * 1969-11-24 1975-04-01 Wenner Gren Medical Lab Aktieb Animal feed supplement
US4362710A (en) * 1980-07-04 1982-12-07 Nissan Gosei Kogyo Co., Ltd. Feeds for baby pigs, process for preparing the same and method of breeding baby pigs
US4980164A (en) * 1986-10-02 1990-12-25 Bio Techniques Laboratories, Inc. Strains of lactobacillus for enhancing feed conversion efficiency
US4946791A (en) * 1986-10-02 1990-08-07 Bio Techniques Laboratories, Inc. Novel strain of Lactobacillus acidophilus
US5374425A (en) * 1987-02-20 1994-12-20 Porter; William L. Animal feed additives
US5360730A (en) * 1987-06-05 1994-11-01 Universal Foods Corporation Zeaxanthin producing strains of Neospongiococcum Excentricum
SE8702435L (en) * 1987-06-11 1988-12-12 Medipharm Ab COULD INCREASE THE PROTEIN CONTENTS IN MILK WITH MILK PRODUCING ANIMALS
FR2616662B1 (en) * 1987-06-16 1994-02-18 Guyomarch Sa Ets FOOD ADDITIVE FOR ANIMALS, FOOD COMPRISING SUCH AN ADDITIVE AND METHOD FOR IMPROVING THE GROWTH OF ANIMALS
US5179020A (en) * 1991-08-19 1993-01-12 Bio Techniques Laboratories, Inc. Antibiotic resistant strain of lactobacillus acidophilus
US5256425A (en) * 1991-08-19 1993-10-26 Bio Techniques Laboratories, Inc. Antibiotic resistant strain of lactobacillus acidophilus

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1040278A (en) * 1963-10-15 1966-08-24 Analyses Et De Rech S Biolog M Bacterial compositions for the regeneration of the intestinal microflora
EP0208818A1 (en) * 1984-01-17 1987-01-21 Seikenkai Foundational Juridical Person Biodeodorizer and the process for the preparation thereof
US4808417A (en) * 1986-12-27 1989-02-28 Toa Pharmaceutical Co., Ltd. Feed additive for fish cultivation
EP0290410A2 (en) * 1987-05-05 1988-11-09 Ewos Aktiebolag Food and feedstuff
WO1989011858A1 (en) * 1988-06-09 1989-12-14 Whitecliffe Laboratories Limited Treatment of immunodeficiency
EP0397227A1 (en) * 1989-05-12 1990-11-14 Bio Serae Laboratoires Sa Method of preparation of an antimicrobial particulate, its product and applications

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0681787A3 (en) * 1994-05-10 1996-10-23 Finnfeeds Int Ltd Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis.
US5624678A (en) * 1994-05-10 1997-04-29 Finnfeeds International Limited Method and composition for treatment and/or prophylaxis of coccidiosis
WO1996015682A1 (en) * 1994-11-22 1996-05-30 Ing. Erich Erber Kommanditgesellschaft Fodder and drinking water additive for improving the resistance to stress and immunity of useful animals
FR2733119A1 (en) * 1995-04-05 1996-10-25 Tsa Fa Hung PROCESS FOR BREEDING CHICKENS
EP0852114A1 (en) * 1997-01-06 1998-07-08 Cobiotex Processes for the systematic eradication of pathogenic agents carried by animals and compositions used in these processes
FR2758051A1 (en) * 1997-01-06 1998-07-10 Cobiotex METHODS OF SYSTEMATICALLY ERADICATING THE CARRYING OF PATHOGENIC AGENTS WITH ANIMALS AND COMPOSITIONS IMPLEMENTED IN SAID METHODS
WO1999003497A1 (en) * 1997-07-18 1999-01-28 Finnfeeds International Ltd. Use of an enzyme for the manufacture of an agent for controlling bacterial infection
US7011964B2 (en) 1997-07-18 2006-03-14 Finnfeeds International Ltd. Use of an enzyme for the manufacture of an agent for controlling bacterial infection
GB2349794A (en) * 1998-10-15 2000-11-15 Dsm Nv Antimicrobial enzymes in animal feed
GB2349794B (en) * 1998-10-15 2001-08-22 Dsm Nv Antimicrobial enzymes in animal feed
WO2000021381A1 (en) * 1998-10-15 2000-04-20 Dsm N.V. Antimicrobial enzymes in animal feed
US7799551B2 (en) 2004-09-01 2010-09-21 Pioneer Hi-Bred International, Inc. Ferulate esterase producing strains and methods of using same
US8211672B2 (en) 2004-09-01 2012-07-03 Pioneer Hi-Bred International, Inc. Ferulate esterase-producing bacterial strain for treating pre-ensiled plant material
US8236537B2 (en) 2004-09-01 2012-08-07 Pioneer Hi-Bred International, Inc. Ferulate esterase producing strains for the enhancement of biogas production
US8409642B2 (en) 2004-09-01 2013-04-02 Pioneer Hi-Bred International, Inc. Ferulate esterase-producing bacterial strain for enhancing plant fiber digestion in an animal
US7919683B2 (en) 2006-11-13 2011-04-05 Pioneer Hi-Bred International, Inc. Cloning and sequencing of the ferulate esterase gene from Lactobacillus buchneri LN4017
WO2012096500A3 (en) * 2011-01-11 2012-11-22 광주시농업기술센터 Probiotic composition for livestock, and method for preparing same
US9822334B2 (en) 2014-03-07 2017-11-21 Pioneer Hi-Bred International, Inc. Rapid acting lactobacillus strains and their use to improve aerobic stability of silage
WO2019095935A1 (en) * 2017-11-20 2019-05-23 济南百斯杰生物工程有限公司 Microecological formulation compatible with glucose oxidase, preparation method therefor and use thereof

Also Published As

Publication number Publication date
AU667070B2 (en) 1996-03-07
EP0623022B1 (en) 1998-12-23
NO942675L (en) 1994-07-15
AU3264093A (en) 1993-08-03
US5718894A (en) 1998-02-17
GB9200891D0 (en) 1992-03-11
JPH07503004A (en) 1995-03-30
FI943387A0 (en) 1994-07-15
NZ246376A (en) 1996-03-26
DE69322766D1 (en) 1999-02-04
ATE174797T1 (en) 1999-01-15
EP0623022A1 (en) 1994-11-09
NO942675D0 (en) 1994-07-15
FI943387L (en) 1994-07-15
CA2128002A1 (en) 1993-07-22

Similar Documents

Publication Publication Date Title
US5718894A (en) Formulation and use of microorganisms in treating livestock
EP1007086B1 (en) Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection
JP4846795B2 (en) Probiotic health and health foods, food and / or drinking water additives and uses thereof
CH667775A5 (en) ANTIBACTERIAL MIXTURE, FOOD OR PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARING FOOD COMPOSITIONS.
JP2015530401A (en) Probiotic composition and prebiotic composition
KR100357766B1 (en) The methods for alleviating body weight loss and reducing harmful bacteria in the intestine of poultry during the feed withdrawal
WO2007034627A1 (en) Additive for animal feed
WO2004089109A1 (en) Feed composition
GB2206028A (en) Antimicrobial preparations
Sarra et al. The lactic microflora of fowl
Tesfaye et al. The effects of probiotics supplementation on milk yield and composition of lactating dairy cows
KR100430298B1 (en) Microorganism preparation complex for using feed additives or treating animal sewage
Lyons Probiotics: an alternative to antibiotics.
US20020156046A1 (en) Sorbic acid product as addition to feedstuffs in agricultural livestock rearing
EP0971032A1 (en) Growth promoting material for useful microorganisms and process for producing the same
KR20080037457A (en) Fish feed composition comprising Bacillus polyfermentus, Bacillus rickeniformis and Saccharomyces cervieira
WO2018165252A1 (en) Feed additive formulation and methods of making and using the same
JP2002507123A (en) Method for improving the effectiveness of probiotics, preparation of nutritional additives and animal feed containing same
Wang et al. Lactic acid bacteria in animal breeding and aquaculture
CN113439803A (en) Complex enzyme preparation capable of replacing feed antibiotics
Lyons Probiotics: An alternative to antibiotics
KR20020072273A (en) Use of propionic bacteria for producing propionic acid and/or propionates in the colon
Lyons et al. Probiotics
Mukodiningsih et al. The Effect of Adding Fermented Waste Cabbage as Probiotic Source to Pellet Calf Starter on Rumen Development and Calf Immune
KR100445292B1 (en) New Enterococcus faecium UBT-M01 having muti-purposed probiotics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA FI GB HU JP KP KR LK MG MN MW NO NZ PL RO RU SD UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1993901859

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2128002

Country of ref document: CA

Ref document number: 08256657

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 246376

Country of ref document: NZ

Ref document number: 943387

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1993901859

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993901859

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载